Clinical Trials
22 trialsNCT03935893 2026-06-01
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Active not recruiting
NCT02978625 2026-05-13
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05947500 2026-05-13
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03271372 2026-05-12
ADAM
University of Washington
Phase 3 Active not recruiting
NCT03583528 2026-05-12
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Active not recruiting
NCT03816332 2026-04-30
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04349436 2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2 Active not recruiting
NCT04291885 2026-04-09
I-MAT
Melanoma and Skin Cancer Trials Limited
Phase 2 Active not recruiting
NCT04869137 2026-04-08
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04792073 2026-04-07
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT06008977 2026-03-25
EX-BOOST
AdventHealth Translational Research Institute
Phase NA Active not recruiting
NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT06056895 2026-01-15
TRICK-MCC
University of Washington
Phase 2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT05594290 2026-01-14
MERCURY
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT05120271 2025-12-05
DUET-1
Sotio Biotech Inc.
Phase 1/2 Active not recruiting
NCT04047251 2025-09-04
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1 Active not recruiting
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting